Tumor xenograft response to redox-active therapies assessed by magnetic resonance imaging using a thiol-bearing DOTA complex of gadolinium

Translational Oncology

Volumn 5, Issue 3, 2012, Pages 190-199

  Guntle, Gerald P ^a   Jagadish, Bhumasamudram ^b   Mash, Eugene A ^b   Powis, Garth ^c   Dorr, Robert T ^d   Raghunand, Natarajan ^a,e  

^a UNIVERSITY OF ARIZONA   (United States)

^b University of Arizona   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; GADOLINIUM; TETRAXETAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION REACTION; PANCREAS CARCINOMA; SCID MOUSE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 84862014023     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11322     Document Type: Article

References (41)

1. Hayes JD and McMahon M (2009). NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34, 176-188.
2. Anderson ME (1998). Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 111-112, 1-14.
3. Chen X, Carystinos GD, and Batist G (1998). Potential for selective modulation of glutathione in cancer chemotherapy. Chem Biol Interact 111-112, 263-275.
4. Pompella A, De Tata V, Paolicchi A, and Zunino F (2006). Expression of γ-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol 71, 231-238.
5. Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, and Dorr RT (2000). Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent Imexon. Biochem Pharmacol 60, 749-758.
6. Lin X, Zhang F, Bradbury CM, Kaushal A, Li L, Spitz DR, Aft RL, and Gius D (2003). 2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res 63, 3413-3417.
7. Coleman MC, Asbury CR, Daniels D, Du J, Aykin-Burns N, Smith BJ, Li L, Spitz DR, and Cullen JJ (2008). 2-Deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med 44, 322-331.
8. Cho H, Koto M, Riesterer O, Molkentine DP, Giri U, Milas L, Story MD, Ha CS, and Raju U (2009). Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study. Anticancer Res 29, 4409-4416.
9. Tuttle S, Horan A, Koch CJ, Held K, Manevich Y, and Biaglow J (1998). Radiation-sensitive tyrosine phosphorylation of cellular proteins: sensitive to changes in GSH content induced by pretreatment with N-acetyl-Lcysteine or L-buthionine-S, R-sulfoximine. Int J Radiat Oncol Biol Phys 42, 833-838.
10. Richardson ME and Siemann DW (1997). Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance. Int J Radiat Oncol Biol Phys 39, 789-795.
11. Renschler MF (2004). The emerging role of reactive oxygen species in cancer therapy. Eur J Can 40, 1934-1940.
12. Liu RM and Gaston Pravia KA (2010). Oxidative stress and glutathione in TGF-β-mediated fibrogenesis. Free Radic Biol Med 48, 1-15.
13. Ballatori N, Krance SM, Marchan R, and Hammond CL (2009). Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol Aspects Med 30, 13-28.
14. Jones DP, Carlson JL, Mody VC, Cai J, Lynn MJ, and Sternberg P (2000). Redox state of glutathione in human plasma. Free Radic Biol Med 28, 625-635.
15. 1H MRS. Magn Reson Med 49, 632-637.
16. Thelwall PE, Yemin AY, Gillian TL, Simpson NE, Kasibhatla MS, Rabbani ZN, Macdonald JM, Blackband SJ, and Gamcsik MP (2005). Noninvasive in vivo detection of glutathione metabolism in tumors. Cancer Res 65, 10149-10153.
17. Kuppusamy P, Li H, Ilangovan G, Cardounel AJ, Zweier JL, Yamada K, Krishna MC, and Mitchell JB (2002). Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res 62, 307-312.
18. Hyodo F, Matsumoto K, Matsumoto A, Mitchell JB, and Krishna MC (2006). Probing the intracellular redox status of tumors with magnetic resonance imaging and redox-sensitive contrast agents. Cancer Res 66, 9921-9928.
19. Gallez B, Bacic G, Goda F, Jiang J, O'Hara JA, Dunn JF, and Swartz HM (1996). Use of nitroxides for assessing perfusion, oxygenation, and viability of tissues: in vivo EPR and MRI studies. Magn Reson Med 35, 97-106.
20. Davis RM, Matsumoto S, Bernardo M, Sowers A, Matsumoto K-I, Krishna MC, and Mitchell JB (2011). Magnetic resonance imaging of organic contrast agents in mice: capturing the whole-body redox landscape. Free Radic Biol Med 50, 459-468.
21. Tu C, Osborne EA, and Louie AY (2009). Synthesis and characterization of a redox-and light-sensitive MRI contrast agent. Tetrahedron 65, 1241-1246.
22. Raghunand N, Guntle GP, Gokhale V, Nichol G, Mash EA, and Jagadish B (2010). Design, synthesis, and evaluation of 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid-derived, redox-sensitive contrast agents for magnetic resonance imaging. J Med Chem 53, 6747-6757.
23. Raghunand N, Jagadish B, Trouard TP, Galons JP, Gillies RJ, and Mash EA (2006). Redox-sensitive contrast agents for MRI based on reversible binding of thiols to serum albumin. Magn Reson Med 55, 1272-1280.
24. Bennett HS (1951). The demonstration of thiol groups in certain tissues by means of a new colored sulfhydryl reagent. Anat Rec 110, 231-247.
25. Asghar K, Reddy BG, and Krishna G (1975). Histochemical localization of glutathione in tissues. J Histochem Cytochem 3, 774-779.
26. Chieco P and Boor PJ (1983). Use of low temperatures for glutathione histochemical stain. J Histochem Cytochem 31, 975-976.
27. Larrauri A, Lopez P, Gomez-Lechon M-J, and Castell JV (1987). A cytochemical stain for glutathione in rat hepatocytes cultured on plastic. J Histochem Cytochem 35, 271-274.
28. Vukovic V, Nicklee T, and Hedley DW (2000). Microregional heterogeneity of non-protein thiols in cervical carcinomas assessed by combined use of HPLC and fluorescence image analysis. Clin Cancer Res 6, 1826-1832.
29. Minchinton AI, Rojas A, Smith A, Soranson JA, Shrieve DC, Jones NR, and Bremner JC (1984). Glutathione depletion in tissues after administration of buthionine sulphoximine. Int J Radiat Oncol Biol Phys 10, 1261-1264.
30. Vukovic V, Nicklee T, and Hedley DW (2001). Differential effects of buthionine sulphoximine in hypoxic and non-hypoxic regions of human cervical carcinoma xenografts. Radiother Oncol 60, 69-73.
31. Iyengar BS, Dorr RT, and Remers WA (2004). Chemical basis for the biological activity of Imexon and related cyanoaziridines. J Med Chem 47, 218-223.
32. Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow HHS, Samulitis B, O'Day S, Grenier K, Hersh E, et al. (2007). Phase 1 trial of Imexon in patients with advanced malignancy. J Clin Oncol 25, 1779-1784.
33. Pourpak A, Meyers RO, Samulitis BK, Chow HHS, Kepler CY, Raymond MA, Hersh E, and DorrRT(2006). Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of Imexon in mice. Anti-Cancer Drugs 17, 1179-1184.
34. Mantoni TS, Schendel RRE, Rodel F, Niedobitek G, Al-Assar O, Masamune A, and Brunner TB (2008). Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther 7, 1806-1815.
35. Desai N, Trieu V, Damascelli B, and Soon-Shiong P (2009). SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Translational Oncol 2, 59-64.
36. Rosenberg A and Knox S (2006). Radiation sensitization with redox modulators: a promising approach. Int J Radiat Oncol Biol Phys 64, 343-354.
37. Moreno-Merlo F, Nicklee T, and Hedley DW (1999). Association between tissue hypoxia and elevated non-protein sulphydryl concentrations in human cervical carcinoma xenografts. Br J Can 81, 989-993.
38. Vukovic V, Nicklee T, and Hedley DW (2002). Multiparameter fluorescence mapping of nonprotein sulfhydryl status in relation to blood vessels and hypoxia in cervical carcinoma xenografts. Int J Radiat Oncol Biol Phys 52, 837-843.
39. Hedley DW, Nicklee T, Moreno-Merlo F, Pintilie M, Fyles A, Milosevic M, and Hill RP (2005). Relations between non-protein sulfhydryl levels in the nucleus and cytoplasm, tumor oxygenation, and clinical outcome of patients with uterine cervical carcinoma. Int J Radiat Oncol Biol Phys 61, 137-144.
40. Pei P, Horan MP, Hille R, Hemann CF, Schwendeman SP, and Mallery SR (2006). Reduced nonprotein thiols inhibit activation and function of MMP-9: implications for chemoprevention. Free Radic Biol Med 41, 1315-1324.
41. Blakytny R, Erkell LJ, and Brunner G (2006). Inactivation of active and latent transforming growth factor beta by free thiols: potential redox regulation of biological action. Intl J Biochem Cell Biol 38, 1363-1373.